School administrators and nurses are encouraged to review applicable state laws and regulations to ensure neffy® (epinephrine ...

Biotech stocks put up a split showing at JPM, where names like BridgeBio, ARS and Harmony stood out with strong preliminary reports.

ARS Pharma intends to submit this repeat-dose NAC study data to the FDA as part of its response to the CRL early in the second quarter of 2024. The randomized, crossover pharmacokinetic (PK ...

Preliminary neffy net product revenue for the fourth quarter of 2024 was approximately $6.5 million, with total net product ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 47.40% ...

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) shares gapped up before the market opened on Tuesday after Raymond James raised their price target on the stock from $26.00 to $28.00. The ...

In a report released today, Ryan Deschner from Raymond James maintained a Buy rating on ARS Pharmaceuticals (SPRY – Research Report), with a ...

The inclusion of neffy on Express Scripts’ Commercial National Formularies significantly expands access to millions of commercially insured patients, improving availability of life-saving ...

Preliminary fourth quarter neffy® net product revenue of approximately $6.5 million Preliminary cash, cash equivalents and short-term investments of $314.0 million at year-end 2024 to support an ...

This expanded access aligns with ARS Pharma’s commitment to reducing barriers to care and improving outcomes for patients who rely on epinephrine during allergy emergencies. ARS Pharma ...

Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) shot up 7.6% during mid-day trading on Monday after Raymond James raised their price target on the stock from $26.00 to $28.00.

Among the numerous clinical trials conducted by ARS Pharma and our licensing partners in support of filings in Japan and China, the Company also conducted a Phase 3 study in Japanese pediatric ...